Robin and Orégane join us to develop a microfluidic system for mechanical sollicitation of cancer spheroids

As part of their engineering studies at ISEN Lille for a master’s degree specialized in Bionanotechnologies, Robin and Orégane arrived in HCS Pharma in May 2021 for a 4-month internship. Their work in HCS Pharma follows a student project during which they designed and computationally simulated a microfluidic device capable Read more…

Development of HCS Pharma in Taïwan with an incubation process in the famous NHRI

We are really pleased to announce that we have officially created a representative office in Taïwan (company 仿生培養技術中心 ID number 90729614) which is directed by our partner, Joseph Chou 周肇隆 ジョーゼフ・チョウ, member of our advisory board. Thanks to Joseph and Professor Szecheng J. Lo, member of our scientific advisory board, all Read more…

We will present our researches on the importance of ECM for drug discovery in Parkinson’s disease at NeuroFrance congress (May 19 to 21 )

The international NeuroFrance congress will take place May, 19, 20 and 21th 2021 (virtual meeting). On this occasion, our PhD student Véronique De Conto will present these works in a poster about the importance of matricial and cellular microenvironment for drug discovery in Parkinson’s disease (summary below). Feel free to Read more…

Join us at Molecular Devices workshop on innovative 3D methods for HCS, March 16-17, 2021

During the next Molecular Devices online event called “From organoids to cell painting: Investigate 3D and complex biology using advanced methods in high-content cellular imaging and analysis” we will present how to generate functional human liver organoids derived from hiPSC in BIOMIMESYS® hydroscaffold. This virtual user meeting and workshop is Read more…

Artificial intelligence to improve 3D cell culture : a milestone for HCS pharma

As you may now, in HCS Pharma we strongly believe that the critical point of the human health evolution in next years is the in vitro 3D cell culture, especially for complex diseases like cancer [1]. It’s why we work hard on our exclusive BIOMIMESYS® technology. As experts in HCS and cell imaging, we must master all the process : 3D biological models, 3D cell culture, volumetric pictures acquisition, 3D reconstruction and segmentation of cells and ECM compounds, 3D parameters extraction and, of course, biological interpretations. As explained in our VisuAI R&D project, the 3D reconstruction and segmentation step is not simple.

Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping

A publication from R. Lane et al, described the use of Small extracellular vesicles (sEVs) reservoir as a biomarker for Glioblastoma tumor subtyping. In this publication Astrocytes, Glioblastoma cell lines, and Glioblastoma patient-derived stem cells were grown in BIOMIMESYS® hydroscaffold. Abstract Glioblastoma (GBM) is one of the most aggressive solid tumors for which treatment options Read more…